PROCEPT (PRCT) Insider Filing: Major RSU and Option Grants to CEO
Rhea-AI Filing Summary
Larry L. Wood, President, CEO and a director of PROCEPT BioRobotics Corporation (PRCT), reported equity awards dated 09/02/2025. The filing shows an acquisition of 182,392 restricted stock units (RSUs) at $0, increasing his beneficial ownership of common stock to 185,595 shares after adjustment for the forfeiture of 2,765 unvested RSUs. The RSUs vest one-quarter on 09/02/2026 and then monthly at one-twelfth of the remaining quarterly amount thereafter, subject to continued service. The filing also discloses a stock option grant for 319,618 shares with an exercise price of $39.57, exercisable through 09/01/2036, vesting one-quarter on 09/02/2026 and then monthly thereafter. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Positive
- Significant service-based equity grants (182,392 RSUs and 319,618 options) align the CEO/director's compensation with long-term performance
- Clear vesting schedules beginning 09/02/2026 provide retention incentives tied to continued service
Negative
- Potential future dilution from 182,392 RSUs and 319,618 options when vested/exercised (size relative to total shares outstanding not provided)
- Unvested RSU forfeiture (2,765 RSUs) indicates prior award adjustments, but materiality is unclear from this filing alone
Insights
TL;DR: Insider compensation grants signal retention incentives; near-term vesting begins in one year and could increase outstanding shares on vesting/exercise.
The transaction shows compensation-driven equity awards rather than open-market purchases or sales. The 182,392 RSUs convert to common shares when vested and carry no cash purchase price, while the 319,618 stock options are exercisable at $39.57 and expire in 2036. Vesting schedules start on 09/02/2026, aligning long-term incentive with continued service. For valuation or dilution analysis, compare these award sizes to total shares outstanding (not provided in the filing). This disclosure is typical for officer/director compensation and does not by itself indicate trading intent.
TL;DR: Grants appear to be standard service-based awards with multi-year vesting, consistent with retention-focused governance practices.
The RSU and option vesting schedules are time-based and contingent on continued service, which is a common governance practice to align executive interests with shareholder value over time. The filing documents a forfeiture of 2,765 unvested RSUs previously granted, which the company adjusted in the ending balance. The use of an attorney-in-fact signature is a routine administrative practice. Material governance implications depend on award size relative to outstanding equity and existing compensation policies (not included in this Form 4).
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 319,618 | $0.00 | -- |
| Grant/Award | Common Stock | 182,392 | $0.00 | -- |
Footnotes (1)
- These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-quarter of the RSUs shall vest on September 2, 2026, with one-twelfth of the remaining RSUs shall vest on each quarter thereafter, subject to the Reporting Person continuing as a service provider through such date. The ending balance was adjusted to reflect the forfeiture (for no consideration) of 2,765 unvested RSUs previously granted to the Reporting Person in April 2024 and June 2025 under the issuer's non-employee director compensation program. The Stock Option was granted on September 2, 2025 and one-quarter of the shares subject to the Stock Option will vest on September 2, 2026, and the remainder shall vest monthly thereafter at the rate of 1/48th of the original number of shares subject to the Stock Option, subject to the Reporting Person continuing as a service provider through such date.